Evaluation of fludarabine phosphate in malignant melanoma : a southwest oncology group study

Twenty-seven evaluable patients with advanced malignant melanoma received fludarabine phosphate in a daily x 5 injection. Initial dosing was based on the presence of previous radiation therapy. There was no response seen in these patients despite appropriate dose escalation. Myelosuppression occurre...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1991-02, Vol.9 (1), p.105-108
Main Authors: KISH, J. A, KOPECKY, K, SAMSON, M. K, VON HOFF, D. D, FLETCHER, W. S, KEMPF, R. A, MUGGIA, F. M
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic - administration & dosage
Antimetabolites, Antineoplastic - adverse effects
Antimetabolites, Antineoplastic - therapeutic use
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Dose-Response Relationship, Drug
Drug Evaluation
Female
Humans
Injections, Intravenous
Male
Medical sciences
Melanoma - drug therapy
Middle Aged
Pharmacology. Drug treatments
Vidarabine Phosphate - administration & dosage
Vidarabine Phosphate - adverse effects
Vidarabine Phosphate - analogs & derivatives
Vidarabine Phosphate - therapeutic use
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Twenty-seven evaluable patients with advanced malignant melanoma received fludarabine phosphate in a daily x 5 injection. Initial dosing was based on the presence of previous radiation therapy. There was no response seen in these patients despite appropriate dose escalation. Myelosuppression occurred without significant sequelae.
ISSN:0167-6997
1573-0646
DOI:10.1007/BF00194559